These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30485777)

  • 21. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
    Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
    Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new Sentinel Network--improving the evidence of medical-product safety.
    Platt R; Wilson M; Chan KA; Benner JS; Marchibroda J; McClellan M
    N Engl J Med; 2009 Aug; 361(7):645-7. PubMed ID: 19635947
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA reporting program is key to safety information.
    Young D
    Am J Health Syst Pharm; 2002 Dec; 59(23):2279, 2284, 2289. PubMed ID: 12489365
    [No Abstract]   [Full Text] [Related]  

  • 24. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 28. How many deaths occur annually from adverse drug reactions in the United States?
    Chyka PA
    Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA Encourages Reporting of Tobacco Product Adverse Experiences.
    Retzky SS
    Chest; 2016 Dec; 150(6):1169-1170. PubMed ID: 27938736
    [No Abstract]   [Full Text] [Related]  

  • 33.
    Portanova J; Murray N; Mower J; Subramanian D; Cohen T
    AMIA Annu Symp Proc; 2019; 2019():717-726. PubMed ID: 32308867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
    Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
    BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
    [No Abstract]   [Full Text] [Related]  

  • 37. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 39. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 40. A curated and standardized adverse drug event resource to accelerate drug safety research.
    Banda JM; Evans L; Vanguri RS; Tatonetti NP; Ryan PB; Shah NH
    Sci Data; 2016 May; 3():160026. PubMed ID: 27193236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.